[an error occurred while processing this directive] | [an error occurred while processing this directive]
Comparison of clinical efficacy between postoperative simultaneous and sequential integrated boost intensity-modulated radiotherapy for high-grade glioma
Li Feng, Wang Guohui, Chang Xiaojing, Li Haonan, Liu Huizhi, Ge Xiaohui
Department of Radiation Oncology, The second hospital of Hebei medical university, Shi Jiazhuang 050000, China
AbstractObjective To compare the efficacy and side effects between simultaneous and sequential integrated boost intensity-modulated radiotherapy after operation for high-grade glioma. Methods We retrospectively analyzed 142 patients with high-grade glioma who underwent postoperative radiotherapy from January 2010 to December 2017. All patients were divided into the simultaneous and sequential integrated boost intensity-modulated radiotherapy groups. Concurrent temozolomide chemotherapy was delivered during radiotherapy in two groups. The follow-up outcomes were statistically compared between two groups. Results For the whole group, the median overall survival (OS) was 24 months, the median progression-free survival (PFS) was 17 months, and the median disease-free survival (DFS) was 25 months. In the simultaneous and sequential integrated boost intensity-modulated radiotherapy groups, the median OS were 27.2 and 21.0 months (P=0.950), the median PFS were 21.2 and 15.0 months (P=0.21), and the median DFS were 28.0 and 18.0 months (P=0.171), and the disease control rates were 92.86% and 85.17%(P=0.541), respectively. There was no statistical difference in OS, PFS, DFS, short-term efficacy and side effects between two groups. However, the conformity index in the simultaneous integrated boost intensity-modulated radiotherapy group was better than that in the sequential integrated boost intensity-modulated radiotherapy group (P=0.032). Conclusions Postoperative simultaneous and sequential integrated boost intensity-modulated radiotherapy yield no statistical differences in the survival, short-term efficacy and side effects in the treatment of high-grade glioma. However, the conformity index in the simultaneous integrated boost intensity-modulated radiotherapy group is significantly better, which can be recommended for postoperative radiotherapy of high-grade glioma.
Corresponding Authors:
Ge Xiaohui, Email:xiaozihuirain@163.com
Cite this article:
Li Feng,Wang Guohui,Chang Xiaojing et al. Comparison of clinical efficacy between postoperative simultaneous and sequential integrated boost intensity-modulated radiotherapy for high-grade glioma[J]. Chinese Journal of Radiation Oncology, 2022, 31(6): 513-518.
Li Feng,Wang Guohui,Chang Xiaojing et al. Comparison of clinical efficacy between postoperative simultaneous and sequential integrated boost intensity-modulated radiotherapy for high-grade glioma[J]. Chinese Journal of Radiation Oncology, 2022, 31(6): 513-518.
[1] Luo C, Xu S, Dai G, et al. Tumor treating fields for high-grade gliomas[J]. Biomed Pharmacother, 2020, 127:110193. DOI:10.1016/j. biopha. 2020. 110193. [2] 赵思任(综述), 李仙锋(审校). 高级别胶质瘤诊断及治疗进展[J]. 中国综合临床, 2016, 32(7):670-672. DOI:10.3760/cma.j.issn.1008-6315.2016.07.028. Zhao SR, Li XF. Progress of the diagnosis and treatment of high-grade gliomas[J]. Clin Med Chin,2016,32(7):670-672. DOI:10.3760/cma.j.issn.1008-6315.2016.07.028. [3] Jiang T, Mao Y, Ma W, et al. CGCG clinical practice guidelines for the management of adult diffuse gliomas[J]. Cancer Lett, 2016, 375(2):263-273. DOI:10.1016/j.canlet.2016.01.024. [4] 国家卫生健康委员会医政医管局. 脑胶质瘤诊疗规范(2018年版)[J]. 中华神经外科杂志, 2019, 35(3):217-239. DOI:10.3760/cma.j.issn.1001-2346.2019.03.001. Medical Administration of National Health Commission. Specifications for the diagnosis and treatment of gliomas (2018 edition)[J]. Chin J Neurosurg, 2019, 35(3):217-239. DOI:10.3760/cma.j.issn.1001-2346.2019.03.001. [5] Sulman EP, Ismaila N, Chang SM. Radiation therapy for glioblastoma:american society of clinical oncology clinical practice guideline endorsement of the american society for radiation oncology guideline[J]. J Oncol Pract, 2017, 13(2):123-127. DOI:10.1200/JOP.2016.018937. [6] Nabors LB, Portnow J, Ahluwalia M, et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(11):1537-1570. DOI:10.6004/jnccn.2020.0052. [7] Stupp R, Brada M, van den Bent MJ, et al. High-grade glioma:ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2014, 25 suppl 3:Ⅲ93-101. DOI:10.1093/annonc/mdu050. [8] Mecca C, Giambanco I, Donato R, et al. Targeting mTOR in glioblastoma:rationale and preclinical/clinical evidence[J]. Dis Markers, 2018, 2018:9230479. DOI:10.1155/2018/9230479. [9] Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs. maintenance temozolomide alone on survival in patients with glioblastoma:A randomized clinical trial[J]. JAMA, 2017, 318(23):2306-2316. DOI:10.1001/jama.2017.18718. [10] Chiesa S, Mazzarella C, Ferro M, et al. PD-0516:Edema or not edema:this the matter in glioblastoma CTV! Hypothesis from two sequential phase Ⅱ studies[J]. Radiother Oncol, 2014, 111:S203-S204. DOI:10.1016/s0167-8140(15)30622-8. [11] Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma:a randomized phase Ⅲ clinical trial[J]. J Clin Oncol, 2013, 31(32):4085-4091. DOI:10.1200/JCO.2013.49.6968. [12] De La Fuente Herman T, Ahmad And S, Vlachaki MT. Intensity modulated radiation therapy versus three dimensional conformal radiation therapy for treatment of high grade glioma:a radiobiological modeling study[J]. J Xray Sci Technol, 2010, 18(4):393-402. DOI:10.3233/XST-2010-0270. [13] Amelio D, Lorentini S, Schwarz M, et al. Intensity-modulated radiation therapy in newly diagnosed glioblastoma:a systematic review on clinical and technical issues[J]. Radiother Oncol, 2010, 97(3):361-369. DOI:10.1016/j.radonc.2010.08.018. [14] Cho KH, Kim JY, Lee SH, et al. Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas[J]. Int J Radiat Oncol Biol Phys, 2010, 78(2):390-397. DOI:10.1016/j.ijrobp.2009.08.029. [15] Panet-Raymond V, Souhami L, Roberge D, et al. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme:a safety and efficacy analysis[J]. Int J Radiat Oncol Biol Phys, 2009, 73(2):473-478. DOI:10.1016/j.ijrobp.2008.04.030. [16] Schreck KC, Grossman SA. Role of temozolomide in the treatment of cancers involving the central nervous system[J]. Oncology (Williston Park), 2018, 32(11):555-560, 569. [17] Lan F, Yang Y, Han J, et al. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κb-dependent pathway downregulating MGMT expression[J]. Int J Oncol, 2016, 48(2):559-568. DOI:10.3892/ijo.2015.3271.
2022, Vol. 31 
